Po-Lan Su1, Chian-Wei Chen1, Yi-Lin Wu2, Chien-Chung Lin3, Wu-Chou Su3. 1. Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 2. Department of Nursing, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 3. Department of Internal Medicine and Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.
Abstract
BACKGROUND: Few studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), afatinib, with that of reversible EGFR-TKIs. Therefore, this study assessed the effectiveness of afatinib, erlotinib, and gefitinib in terms of OS (overall survival) and progression-free survival (PFS) in EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) patients. METHODS: Patients with EGFR mutation-positive advanced NSCLC who sought treatment from December 2013 to June 2018, at a tertiary referral center were retrospectively analyzed. These patients were treated with afatinib or a reversible EGFR-TKI (erlotinib or gefitinib) until disease progression, intolerable adverse events, or death. The Kaplan-Meier and log-rank tests were then used to compare the OS and PFS of the patients. We further analyzed the survival differences among the subgroup of patients without brain metastases. RESULTS: Of the 363 patients enrolled, 134 and 229 received first-line afatinib and first-line reversible EGFR-TKI, respectively. Those given afatinib had better OS (39.3 vs. 26.0 months; HR 0.65, P = 0.033) and PFS (14.1 vs.11.2 months; HR 0.58, P < 0.001). Of the 246 patients without brain metastases, 93 and 153 received first-line afatinib and a first-line reversible EGFR-TKI, respectively. Those given afatinib had a better OS (52.6 vs. 24.9 months; HR 0.62, P = 0.0030) and PFS (17.7 vs. 11.1 months; HR 0.51, P < 0.001). The survival benefit was more significant in the subgroup of patients with L858R substitutions. CONCLUSIONS: The results indicated that afatnib resulted in significantly better OS and PFS than gefitnib and erlotinib for EGFR mutation-positive advanced NSCLC patients without brain metastases. KEY POINTS: Significant findings of the study Afatnib resulted in significantly better overall survival and progression-free survival than gefitnib and erlotinib for EGFR mutation-positive advanced non-small cell lung cancer patients without brain metastases. What this study adds This study helps fill the gap in our limited understanding of the differences in the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), afatinib, with that of reversible EGFR-TKIs.
BACKGROUND: Few studies have compared the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), afatinib, with that of reversible EGFR-TKIs. Therefore, this study assessed the effectiveness of afatinib, erlotinib, and gefitinib in terms of OS (overall survival) and progression-free survival (PFS) in EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) patients. METHODS:Patients with EGFR mutation-positive advanced NSCLC who sought treatment from December 2013 to June 2018, at a tertiary referral center were retrospectively analyzed. These patients were treated with afatinib or a reversible EGFR-TKI (erlotinib or gefitinib) until disease progression, intolerable adverse events, or death. The Kaplan-Meier and log-rank tests were then used to compare the OS and PFS of the patients. We further analyzed the survival differences among the subgroup of patients without brain metastases. RESULTS: Of the 363 patients enrolled, 134 and 229 received first-line afatinib and first-line reversible EGFR-TKI, respectively. Those given afatinib had better OS (39.3 vs. 26.0 months; HR 0.65, P = 0.033) and PFS (14.1 vs.11.2 months; HR 0.58, P < 0.001). Of the 246 patients without brain metastases, 93 and 153 received first-line afatinib and a first-line reversible EGFR-TKI, respectively. Those given afatinib had a better OS (52.6 vs. 24.9 months; HR 0.62, P = 0.0030) and PFS (17.7 vs. 11.1 months; HR 0.51, P < 0.001). The survival benefit was more significant in the subgroup of patients with L858R substitutions. CONCLUSIONS: The results indicated that afatnib resulted in significantly better OS and PFS than gefitnib and erlotinib for EGFR mutation-positive advanced NSCLCpatients without brain metastases. KEY POINTS: Significant findings of the study Afatnib resulted in significantly better overall survival and progression-free survival than gefitnib and erlotinib for EGFR mutation-positive advanced non-small cell lung cancerpatients without brain metastases. What this study adds This study helps fill the gap in our limited understanding of the differences in the efficacy of the irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), afatinib, with that of reversible EGFR-TKIs.
Authors: Chee Khoon Lee; Yi-Long Wu; Pei Ni Ding; Sarah J Lord; Akira Inoue; Caicun Zhou; Tetsuya Mitsudomi; Rafael Rosell; Nick Pavlakis; Matthew Links; Val Gebski; Richard J Gralla; James Chih-Hsin Yang Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares Journal: Lancet Oncol Date: 2016-04-12 Impact factor: 41.316
Authors: Tony S Mok; Ying Cheng; Xiangdong Zhou; Ki Hyeong Lee; Kazuhiko Nakagawa; Seiji Niho; Min Lee; Rolf Linke; Rafael Rosell; Jesus Corral; Maria Rita Migliorino; Adam Pluzanski; Eric I Sbar; Tao Wang; Jane Liang White; Yi-Long Wu Journal: J Clin Oncol Date: 2018-06-04 Impact factor: 44.544
Authors: Pedro N Aguiar; Benjamin Haaland; Wungki Park; Pui San Tan; Auro Del Giglio; Gilberto de Lima Lopes Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: J J Yang; Q Zhou; H H Yan; X C Zhang; H J Chen; H Y Tu; Z Wang; C R Xu; J Su; B C Wang; B Y Jiang; X Y Bai; W Z Zhong; X N Yang; Y L Wu Journal: Br J Cancer Date: 2017-01-19 Impact factor: 7.640